A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Trial Profile

A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 16 Sep 2016 Results assessing postprandial glucose (PPG) metabolism, lipid (PPL) metabolism and gastric emptying (GE), presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 16 Sep 2016 Results confirming semaglutide-induced body weight loss through various possible mechanisms, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 23 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top